Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide
Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide
Prospective, observational pilot study of ten post-transplant patients presenting with
 diarrhea while taking Mycophenolate Mofetil (MMF). These patients will undergo a standard
 workup to confirm MMF induced diarrhea. A stool fecal calprotectin will be measured to
 determine if it may be helpful in confirming the diagnosis of MMF associated diarrhea. Once
 the diagnosis is confirmed, the patients will then be treated with a short course of
 subcutaneous Octreotide which has been shown to cure this type of diarrhea.
Inclusion Criteria:

 -  Male and female patients between the ages of 18 and 75 years old who are solid organ
 transplant recipients followed at Toronto General Hospital on MMF referred to
 gastroenterology for diarrhea.

 Exclusion Criteria:

 1. Subjects with a known history of IBD or GVHD of the bowel.

 2. Any subject receiving Octreotide for another indication.

 3. Any patient unable to undergo endoscopy.

 4. Any patient with a contraindication to Octreotide therapy.